文献速递儿童青少年精神

母亲孕前及孕期使用叶酸和复合维生素与子代自闭症谱系障碍风险的关联

Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

一项以色列病例对照队列研究纳入45 300名儿童,随访至2015年,发现母亲孕前及孕期使用叶酸和/或复合维生素与子代自闭症谱系障碍风险降低显著相关(孕前RR 0.39,孕期RR 0.27),敏感性分析结果稳健。

要点

  • 孕前使用叶酸和/或复合维生素与子代ASD风险降低相关(RR 0.39)。
  • 孕期使用叶酸和/或复合维生素与子代ASD风险降低相关(RR 0.27)。
  • 单独使用叶酸或复合维生素在孕前及孕期均与ASD风险降低相关。

核心结论

  • 母亲孕前及孕期使用叶酸和复合维生素与子代ASD风险降低相关。

研究设计与样本

  • 病例对照队列研究,纳入45 300名2003年至2007年出生的以色列儿童,随访至2015年。
  • 病例为所有诊断为ASD的儿童,对照为随机抽取的33%活产儿。

主要发现

  • 572名(1.3%)儿童诊断为ASD。
  • 孕前使用叶酸和/或复合维生素与子代ASD风险降低相关(RR 0.39,95%CI 0.30-0.50,P<.001)。
  • 孕期使用叶酸和/或复合维生素与子代ASD风险降低相关(RR 0.27,95%CI 0.22-0.33,P<.001)。
  • 孕前使用叶酸RR 0.56(95%CI 0.42-0.74,P=.001),孕期使用叶酸RR 0.32(95%CI 0.26-0.41,P<.001)。
  • 孕前使用复合维生素RR 0.36(95%CI 0.24-0.52,P<.001),孕期使用复合维生素RR 0.35(95%CI 0.28-0.44,P<.001)。

临床怎么用

  • 对于备孕及孕期女性,可考虑建议使用叶酸和复合维生素以降低子代ASD风险。

局限性

  • 敏感性分析结果总体稳健,但研究为观察性设计,不能完全排除残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The association of maternal use of folic acid and multivitamin supplements before and during pregnancy with the risk of autism spectrum disorder (ASD) in offspring is unclear. OBJECTIVE: To examine the associations between the use of maternal folic acid and multivitamin supplements before and during pregnancy and the risk of ASD in offspring. DESIGN, SETTING, AND PARTICIPANTS: A case-control cohort study of 45 300 Israeli children born between January 1, 2003, and December 31, 2007, were followed up from birth to January 26, 2015, for the risk of ASD. The cases were all children diagnosed with ASD and the controls were a random sample of 33% of all live-born children. EXPOSURES: Maternal vitamin supplements were classified for folic acid (vitamin B9), multivitamin supplements (Anatomical Therapeutic Chemical A11 codes vitamins A, B, C, and D), and any combination thereof exposed in the intervals before and during pregnancy. MAIN OUTCOMES AND MEASURES: The association between maternal vitamin supplementation and the risk of ASD in offspring was quantified with relative risks (RRs) and their 95% CIs fitting Cox proportional hazards regression models adjusted for confounders. Sensitivity analyses were performed to test the robustness of the results. RESULTS: Of the 45 300 children in the study (22 090 girls and 23 210 boys; mean [SD] age, 10.0 [1.4] years at the end of follow-up), 572 (1.3%) received a diagnosis of ASD. Maternal exposure to folic acid and/or multivitamin supplements before pregnancy was statistically significantly associated with a lower likelihood of ASD in the offspring compared with no exposure before pregnancy (RR, 0.39; 95% CI, 0.30-0.50; P < .001). Maternal exposure to folic acid and/or multivitamin supplements during pregnancy was statistically significantly associated with a lower likelihood of ASD in offspring compared with no exposure during pregnancy (RR, 0.27; 95% CI, 0.22-0.33; P < .001). Corresponding RRs were estimated for maternal exposure to folic acid before pregnancy (RR, 0.56; 95% CI, 0.42-0.74; P = .001), maternal exposure to folic acid during pregnancy (RR, 0.32; 95% CI, 0.26-0.41; P < .001), maternal exposure to multivitamin supplements before pregnancy (RR, 0.36; 95% CI, 0.24-0.52; P < .001), and maternal exposure to multivitamin supplements during pregnancy (RR, 0.35; 95% CI, 0.28-0.44; P < .001). The results generally remained statistically significant across sensitivity analyses. CONCLUSIONS AND RELEVANCE: Maternal exposure to folic acid and multivitamin supplements before and during pregnancy is associated with a reduced risk of ASD in the offspring compared with the offspring of mothers without such exposure.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Levine SZ, Kodesh A, Viktorin A, et al. Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring. JAMA Psychiatry. 2018. PMID: 29299606. doi:10.1001/jamapsychiatry.2017.4050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。